In this segment of the weekly health-care show, analyst David Williamson explains why investors need to have Arena Pharmaceuticals (ARNA +0.00%) on their radar. Watch and find out how a big EU approval decision, DEA scheduling, and the first quarter sales report of competitor Vivus's (VVUS +0.00%) Qsymia could impact the stock in the coming weeks.
